(MENAFN- GlobeNewsWire - Nasdaq) Emerging market opportunities include advanced therapies for RSV, COVID-19, UTIs, HIV, and fungal infections, with promising candidates such as Moderna's mRNA assets, GSK's TBP-PI-HBr, and Armata's AP-SA02. Focus on innovative strategies in viral, bacterial, and fungal infection management.

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "IDWeek: Annual Meeting 2025 Highlights" report has been added to ResearchAndMarkets's offering.
IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.
IDWeek 2025 took place in Atlanta, Georgia, between 19-22 October 2025.
The analyst's infectious diseases team attended industry-sponsored and scientific sessions where key therapies were featured, the contents of which were analyzed to create this IDWeek 2025 Highlights report.
Report Scope

Indications, companies, and therapies discussed in the report are as follows:

• Respiratory syncytial virus (RSV)
• Moderna - mRNA-1345 (mRESVIA)
• Enanta Pharmaceuticals - EDP-323
• COVID-19
• Moderna - mRNA-1273.815 (Spikevax XBB.1.5)
• Invivyd - Pemivibart (Pemgarda)
• Complicated urinary tract infections (cUTIs)/acute pyelonephritis
• GSK and Spero Therapeutics - Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr)
• HIV
• ST Pharm - Pirmitegravir (STP0404)
• Nontuberculous mycobacteria (NTM)
• Paratek Pharmaceuticals - Omadacycline (Nuzyra)
• Gonorrhea
• Innoviva Specialty Therapeutics - Zoliflodacin
• Complicated Staphylococcus aureus bacteremia (SAB)
• Armata Pharmaceuticals - AP-SA02
• Fungal Infections
• Elion Therapeutics - EL219
• Herpes simplex virus (HSV)
• AiCuris - Pritelivir

Reasons to Buy
This powerpoint-based deliverable provides analysis on key presentations from the conference, and what they mean for your strategy, covering disease areas such as HIV, COVID-19, RSV, NTM, UTIs, and more.
Inside the report you'll find:

• Emerging trends in prophylactic or therapeutic strategies for the management of viral, bacterial, and fungal infections
• Insights into the disease areas that took precedence at the conference
• Key takeaways from headline sessions and late-breaking data
• Clinical and commercial implications of notable presentations

Key Topics Covered:
1. Introduction
1.1. Table of contents
1.2. Report overview
1.3. Abbreviations
2. Conference Overview
3. Key Presentations
3.1. Respiratory syncytial virus (RSV)
3.2. COVID-19
3.3. Complicated urinary tract infections (cUTIs)/acute pyelonephritis (AP)
3.4. HIV
3.5. Nontuberculous mycobacteria (NTM)
3.6. Gonorrhea
3.7. Complicated Staphylococcus aureus bacteremia (SAB)
3.8. Fungal infections
3.9. Herpes simplex virus (HSV)
4. Appendix
5. Contact the Publisher
Companies Featured

• Moderna
• Enanta Pharmaceuticals
• Invivyd
• GSK
• Spero Therapeutics
• ST Pharm
• Paratek Pharmaceuticals
• Innoviva Specialty Therapeutics
• Armata Pharmaceuticals
• Elion Therapeutics
• AiCuris

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN01122025004107003653ID1110418075